Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Frank Roberts

Principal, Health & Life Sciences, Oliver Wyman

Rapid Cost Transformation to Establish a Baseline

Sixty-five percent of health plans with total membership in group commercial are at high-risk for negative profitability.

Partner, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman
Partner, Financial Services, Oliver Wyman
Senior Consultant, Oliver Wyman

Cost Transformation Amidst Uncertainty

Establish and aim towards a North Star to ensure your organization heads in the direction you want it to.

Partner, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman
Senior Consultant, Oliver Wyman

Cost as an Investment (Not an Inconvenience)

But it's always been done this way. Until now.

Partner, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman

20 percent of care is unnecessary. Peer physician assessment of practice patterns is helping solve healthcare's inappropriate care crisis.

Principal, Health & Life Sciences, Oliver Wyman
Partner and Chief Medical Officer, Health & Life Sciences, Oliver Wyman

Physicians are best positioned to curtail the $265 billion wasted annually on unneeded care.

Global Head, Health Services, Oliver Wyman
Professor of Surgery and Health Policy, Johns Hopkins Medicine
Principal, Health & Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe

Transparency into peer practices may curb care overuse. But just prescribing fewer antibiotics isn't a simple solution.

Partner and Chief Medical Officer, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman

Insights into how hospital systems can manage Medicaid populations without abandoning their mission – or their bottom line.

Partner, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman

To what extent could intelligent analytic tools impact healthcare providers in the future?

Principal, Health & Life Sciences, Oliver Wyman